These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8747771)

  • 21. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy.
    Avery RK; Adal KA; Longworth DL; Bolwell BJ
    Bone Marrow Transplant; 2000 Oct; 26(7):763-7. PubMed ID: 11042658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital.
    Grow WB; Moreb JS; Roque D; Manion K; Leather H; Reddy V; Khan SA; Finiewicz KJ; Nguyen H; Clancy CJ; Mehta PS; Wingard JR
    Bone Marrow Transplant; 2002 Jan; 29(1):15-9. PubMed ID: 11840139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMV prophylaxis in allogeneic BMT with ganciclovir and CMV immune globulin.
    Patton WN; Carter C; Bienz N; Lamb T; Boughton BJ; Franklin IM
    Bone Marrow Transplant; 1991; 7 Suppl 2():44. PubMed ID: 1652330
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of cytomegalovirus infections in bone marrow transplant in Trieste: seven years' experience.
    D'Agaro P; Andolina M; Burgnich P; Samar E; Campello C
    Haematologica; 2000 Nov; 85(11 Suppl):54-7. PubMed ID: 11268325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.
    Prentice HG; Kho P
    Bone Marrow Transplant; 1997 Jan; 19(2):135-42. PubMed ID: 9116610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital.
    Ward KN; Roberts IA; van Rhee F
    Bone Marrow Transplant; 1994 Feb; 13(2):230-1. PubMed ID: 8205098
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
    Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
    Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
    Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
    Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
    Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
    Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.